Press release
Hemophilia B Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Alnylam, ApcinteX, Bioverativ, CSL Behring, Genzyme, LFB Pharma, Novo Nordisk, Pfizer, Sangamo, Sobi, UniQure
"Hemophilia B Pipeline Insight, 2023" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Hemophilia B Therapeutics Market.
The report provides a detailed description of the Hemophilia B drugs, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any). The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.
Get a Detailed Overview of the Hemophilia B Clinical Trial Activities and Regulatory Developments in the domain @
https://www.delveinsight.com/report-store/hemophilia-b-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Hemophilia B Pipeline Analysis
The report provides insights into:
• The report provides detailed insights into the key companies that are developing Hemophilia B therapies.
• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Hemophilia B treatment.
• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• It navigates the emerging Hemophilia B drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement in the Hemophilia B treatment market.
Learn More about the Clinical and Commercial Development Activities in the Hemophilia B Therapeutics Domain @
https://www.delveinsight.com/report-store/hemophilia-b-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Hemophilia B Therapeutics Analysis
There is no cure for hemophilia B till now, but there are treatments for the condition. There are two main approaches to treatment: Preventative treatment and On-demand treatment.
The most common treatment for hemophilia B is called Replacement therapy. Concentrates of clotting factor IX are the foundation of this treatment and are administered as an infusion. BeneFIX, Rixubis, Ixinity, Alprolix, Idelvion, and Rebinyn are some available recombinant factor IX products in the US. Plasma-derived factor IX Concentrates and Fresh Frozen Plasma are also used for the treatment.
Individuals with severe hemophilia B may receive regular infusions to prevent bleeding episodes. This is called prophylactic therapy and is intended to prevent bleeds before they occur.
To accomplish and meet these unmet needs companies like Novo Nordisk, Sanofi, Pfizer, Catalyst Biosciences, uniQure, and others, are coming up with novel therapeutic approaches that can entirely change the treatment landscape of Hemophilia B. If launched these emerging potential candidates could pose an adverse threat to current Hemophilia B pharmaceuticals giants, by means of their potential to transform the standard of care for Hemophilia B patients.
In November 2022, the US FDA approved HEMGENIX (etranacogene dezaparvovec) developed by uniQure Pharmaceuticals. It is an adeno-associated virus vector-based gene therapy to treat adults with Hemophilia B (congenital Factor IX deficiency) who currently use Factor IX prophylaxis therapy or have a current or historical life-threatening hemorrhage or have repeated, serious spontaneous bleeding episodes.
Hemophilia B Companies in the Therapeutics Market Include:
• Alnylam Pharmaceuticals
• ApcinteX Ltd
• Bioverativ Therapeutics
• CSL Behring
• Freeline Therapeutics
• Genzyme, a Sanofi Company
• HEMA Biologics
• LFB Pharmaceuticals
• Novo Nordisk
• Pfizer
• Sangamo Therapeutics
• Sobi
• Spark Therapeutics
• UniQure Biopharma B.V.
And Many Others
Emerging and Marketed Hemophilia B Therapies Covered in the Report Include:
• Alprolix: Bioverativ Therapeutics/Sobi
• AMT-060: UniQure Biopharma B.V.
• Concizumab (NN7415): Novo Nordisk
• Concizumab: Novo Nordisk
• Etranacogene dezaparvovec (AMT-061): UniQure Biopharma B.V./ CSL Behring
• Fidanacogene elaparvovec (SPK-9001/PF-06838435): Pfizer/Spark Therapeutics
• Fitusiran: Genzyme, a Sanofi Company/ Alnylam Pharmaceuticals
• FLT180a: Freeline Therapeutics
• Idelvion: CSL Behring
• Marstacimab (PF-06741086): Pfizer
• Rebinyn (Nonacog beta pegol): Novo Nordisk
• SB-FIX: Sangamo Therapeutics
• SerpinPC: ApcinteX Ltd
• Sevenfact (coagulation factor VIIa [recombinant]-jncw): HEMA Biologics/LFB Pharmaceuticals
• Verbrinacogene setparvovec (FLT-180a): Freeline Therapeutics
And Many More
Get an in-depth Assessment of the Emerging Therapies and Hemophilia B Companies Actively Working in the Market @
https://www.delveinsight.com/sample-request/hemophilia-b-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
The Report Covers the Emerging Hemophilia B Therapies Under Different Phases of Clinical Development Like -
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued and inactive candidates
Request for Sample PDF to Understand More About the Hemophilia B Treatment Outlook and Future Perspectives @
https://www.delveinsight.com/sample-request/hemophilia-b-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Table of Content
1. Report Introduction
2. Executive Summary
3. Hemophilia B Current Treatment Patterns
4. Hemophilia B - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Hemophilia B Late-Stage Products (Phase-III)
7. Hemophilia B Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Hemophilia B Discontinued Products
13. Hemophilia B Product Profiles
14. Hemophilia B Companies
15. Hemophilia B Drugs
16. Dormant and Discontinued Products
17. Hemophilia B Unmet Needs
18. Hemophilia B Future Perspectives
19. Hemophilia B Analyst Review
20. Appendix
21. Report Methodology
Get Detailed Insights About the Reports Offerings @
https://www.delveinsight.com/sample-request/hemophilia-b-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
------------------------------------------------------------------------------------------------------------------------------
Discover DelveInsight's Comprehensive Market Research and Consulting Services:
https://www.delveinsight.com/market-research
Elevate your industry insights with our comprehensive medical devices market assessment reports. Visit to gain a strategic edge through expert analysis and in-depth coverage of the latest trends, innovations, and market dynamics, at:
https://www.delveinsight.com/medical-devices
Empowering Cancer Care: DelveInsight's oncology consulting services offer personalized guidance and cutting-edge expertise to navigate the ongoing clinical, commercial, and regulatory developments, visit for more details:
https://www.delveinsight.com/oncology
Other Trending Healthcare Reports by DelveInsight
Tenosynovitis Market
https://www.delveinsight.com/report-store/tenosynovitis-market
Checkpoint Inhibitor Refractory Cancer Market
https://www.delveinsight.com/report-store/checkpoint-inhibitor-refractory-cancer-market
Encephalomyelitis Market
https://www.delveinsight.com/report-store/encephalomyelitis-market
FENEBRUTINIB Market
https://www.delveinsight.com/report-store/fenebrutinib-emerging-insight-and-market-forecast
Non-Muscle Invasive Bladder Cancer Market
https://www.delveinsight.com/report-store/non-muscle-invasive-bladder-cancer-market
Nrg1 Fusion Cancer Pipeline Insight
https://www.delveinsight.com/report-store/nrg1-fusion-cancer-pipeline-insight
Acute Pyelonephritis Market
https://www.delveinsight.com/report-store/acute-pyelonephritis-market
Chronic Refractory Gout Market
https://www.delveinsight.com/report-store/chronic-refractory-gout-market
Complicated Urinary Tract Infections Market
https://www.delveinsight.com/report-store/complicated-urinary-tract-infections-market
Congestive Heart Failure (CHF) Market
https://www.delveinsight.com/report-store/congestive-heart-failure-market
Glomerulonephritis Market
https://www.delveinsight.com/report-store/glomerulonephritis-market
Metastatic Uveal Melanoma (MUM) Market
https://www.delveinsight.com/report-store/metastatic-uveal-melanoma-mum-market
Musculoskeletal Pain Market
https://www.delveinsight.com/report-store/musculoskeletal-pain-market
Recurrent Head And Neck Cancer Squamous Cell Carcinoma Market
https://www.delveinsight.com/report-store/recurrent-head-and-neck-cancer-squamous-cell-carcinoma-market
Dysthymia Market
https://www.delveinsight.com/report-store/dysthymia-market
Limb Girdle Muscular Dystrophy (LGMD) Market
https://www.delveinsight.com/report-store/limb-girdle-muscular-dystrophy-lgmd-market
Lower-Limb Spasticity Market
https://www.delveinsight.com/report-store/lower-limb-spasticity-market
Hemiplegia Market
https://www.delveinsight.com/report-store/hemiplegia-market
Global Kinase Inhibitor in Autoimmune Diseases Market
https://www.delveinsight.com/report-store/global-kinase-inhibitor-in-autoimmune-diseases-market
Hereditary Spastic Paraplegias Market
https://www.delveinsight.com/report-store/hereditary-spastic-paraplegias-market
Amebiasis Market
https://www.delveinsight.com/report-store/amebiasis-market
Galactosemia Market
https://www.delveinsight.com/report-store/galactosemia-market
Generalized Pustular Psoriasis Market
https://www.delveinsight.com/report-store/generalized-pustular-psoriasis-market
Hepatic Impairment Market
https://www.delveinsight.com/report-store/hepatic-impairment-market
Tuberous Sclerosis Complex Market
https://www.delveinsight.com/report-store/tuberous-sclerosis-complex-market
Amyloidosis Market
https://www.delveinsight.com/report-store/amyloidosis-market
BRAF-Mutant Metastatic Melanoma Market
https://www.delveinsight.com/report-store/braf-mutant-metastatic-melanoma-market
Candidemia Market
https://www.delveinsight.com/report-store/candidemia-market
Hepatitis D Market
https://www.delveinsight.com/report-store/hepatitis-d-market
Hyperkalemia Market
https://www.delveinsight.com/report-store/hyperkalemia-market
Vasomotor symptoms (Hot flashes/Night sweats) Market
https://www.delveinsight.com/report-store/vasomotor-symptoms-market
Balloon Valvuloplasty Device Market
https://www.delveinsight.com/report-store/balloon-valvuloplasty-market
Choroideremia Market
https://www.delveinsight.com/report-store/choroideremia-market
Chronic Hand Eczema Market
https://www.delveinsight.com/report-store/chronic-hand-eczema-market
Complex Regional Pain Syndrome Market
https://www.delveinsight.com/report-store/complex-regional-pain-syndrome-crps-market
Diffuse Large B-cell Lymphoma Market
https://www.delveinsight.com/report-store/diffuse-large-b-cell-lymphoma-market
Hypersomnia Market
https://www.delveinsight.com/report-store/hypersomnia-market
Lamellar Ichthyosis (LI) Market
https://www.delveinsight.com/report-store/lamellar-ichthyosis-market
Ulcerative Colitis (UC) Market
https://www.delveinsight.com/report-store/ulcerative-colitis-uc-market
Vernal Keratoconjunctivitis Market
https://www.delveinsight.com/report-store/vernal-keratoconjunctivitis-market-insight
Endocarditis Market
https://www.delveinsight.com/report-store/endocarditis-market
Essential Thrombocythemia (ET) Market
https://www.delveinsight.com/report-store/essential-thrombocythemia-et-market-insights
Hepatorenal Syndrome Market
https://www.delveinsight.com/report-store/hepatorenal-syndrome-market
Pancreatic Ductal Carcinoma Market
https://www.delveinsight.com/report-store/pancreatic-ductal-carcinoma-market
Tenosynovial Giant Cell Tumors (TSGCTs) Market
https://www.delveinsight.com/report-store/tenosynovial-giant-cell-tumors-tsgcts-market
Trauma Fixation Devices Market
https://www.delveinsight.com/report-store/trauma-devices-market
Usher Syndrome Market
https://www.delveinsight.com/report-store/usher-syndrome-market
Vulvar Squamous Cell Carcinoma Market
https://www.delveinsight.com/report-store/vulvar-squamous-cell-carcinoma-market
Wide Neck Bifurcation Intracranial Aneurysms Market
https://www.delveinsight.com/report-store/wide-neck-bifurcation-intracranial-aneurysms-market
Contact Info:
Shruti Thakur
Manager - Marketing & International Branding
Email: info@delveinsight.com
428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Hemophilia B Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Alnylam, ApcinteX, Bioverativ, CSL Behring, Genzyme, LFB Pharma, Novo Nordisk, Pfizer, Sangamo, Sobi, UniQure here
News-ID: 3275700 • Views: …
More Releases from DelveInsight Business Research LLP
Genital Warts Pipeline Insights Report 2025 | DelveInsight
DelveInsight's, "Genital Warts Pipeline Insight 2025" report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Genital Warts pipeline landscape. It covers the Genital Warts pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight and stay ahead…
Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
DelveInsight's "Traumatic Brain Injury Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Tthe raumatic Brain Injury pipeline landscape. It covers the Traumatic Brain Injury pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Traumatic Brain Injury pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore…
Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
DelveInsight's, "Bone Metastases Pipeline Insight, 2025," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Bone Metastases pipeline landscape. It covers the Bone Metastasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bone Metastasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight…
Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsi …
DelveInsight's "Acquired Immunodeficiency Syndrome Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Acquired Immunodeficiency Syndrome, historical and forecasted epidemiology as well as the Acquired Immunodeficiency Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the Acquired Immunodeficiency Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acquired Immunodeficiency Syndrome Market…
More Releases for Hemophilia
Rising Occurrence Of Genetic Abnormalities Fuels Hemophilia Market Growth: Stren …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts
What Is the Expected CAGR for the Hemophilia Market Through 2025?
In recent times, there has been a significant expansion in the hemophilia market. The market, which stood at $13.83 billion in 2024, is projected to inflate to $15.13 billion in 2025, exhibiting a compound annual growth rate (CAGR)…
Global Hemophilia Market Size & Trends
According to a new market research report published by Global Market Estimates, the global hemophilia market is projected to grow at a CAGR of 6.8% from 2023 to 2028.
During the forecast period, the global hemophilia market is anticipated to experience growth due to advancements in medical research, an increase in hemophilia incidence, and rising awareness and diagnosis.
Browse 147 Market Data Tables and 115 Figures spread through 163 Pages and…
Acquired Hemophilia Treatment Market - Embracing Hope, Defying Hemophilia: Trans …
Newark, New Castle, USA: The "Acquired Hemophilia Treatment Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Acquired Hemophilia Treatment Market: https://www.growthplusreports.com/report/acquired-hemophilia-treatment-market/7748
This latest report researches the industry structure,…
Hemophilia Market
Hemophilia is an inherited genetic syndrome which impairs body-2019s capability to control blood clotting or coagulation. The episodes of bleeding mainly depend on the severity of hemophilia issue. There are two major kinds of hemophilia namely Hemophilia A & Hemophilia B. Hemophilia A is considered to be five times more prevailing as compared to hemophilia B. Occurrence of hemophilia A is found in one out of five or six thousand…
Global Hemophilia Therapeutics Market By Drug (Advate, NovoSeven, Kogenate/Koval …
ReportsWorldwide has announced the addition of a new report title Global Hemophilia Therapeutics Market By Drug (Advate, NovoSeven, Kogenate/Kovaltry, Feiba), By Type of Hemophilia (Hemophilia A, Hemophilia B), By Treatment (On-Demand, Prophylaxis), By Therapy (Replacement , Immune Tolerance Induction ) Outlook 2022 to its growing collection of premium market research reports.
Hemophilia is an inherited bleeding disorder that slows the blood clotting process. The people suffering from this condition experience prolonged…
In-depth analysis of the Global Hemophilia Market: hemophilia A, hemophilia B, h …
Latest industry research report on: Global Hemophilia Market | Industry Size, Share, Research, Reviews, Analysis, Strategies, Demand, Growth, Segmentation, Parameters, Forecasts
Request For Sample Report @ http://www.marketresearchreports.biz/sample/sample/1064504
The hemophilia market has entered into an era of unprecedented growth rate with a variety of treatment options. Development of new therapeutics along with expansion in the current treatment options has presented new opportunities to the market. Hemophilia being an inherited genetic bleeding disorder causes…
